Clinical trial

Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

NCT00544167

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-05-01

PhaseNA

Study timeline

Study start (unknown)2007-05-01Date precision: month

Registry last updated2013-04-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

DoxorubicinDRUG · verified · RxNorm: doxorubicin

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

PaclitaxelDRUG · verified · RxNorm: paclitaxel

SorafenibDRUG · verified · RxNorm: sorafenib

Sponsors & collaborators

SCRI Development Innovations, LLClead sponsor

Bayercollaborator

Mapped research locations

NashvilleTennessee, United States1 JacksonvilleFlorida, United States1 OrlandoFlorida, United States1 OmahaNebraska, United States1 LouisvilleKentucky, United States1 Grand RapidsMichigan, United States1 ChattanoogaTennessee, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00544167 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.